Combination therapy with radioembolization (yttrium-90)-resin microspheres followed by nivolumab has shown a promising response rate of 30.6% in a Phase II trial (CA209-678) for advanced hepatocellular carcinoma (HCC) The response mechanisms and relevant biomarkers remain unknown .